Clinical analysis and evaluation of the results of adjuvant treatment (radiotherapy and chemotherapy) in ovarian carcinoma.
The present study was carried out on the material of 486 ovarian cancer patients who received radiotherapy and chemotherapy as adjuvant treatment at the Oncological Gynaecology Clinic at the Maria Skłodowska-Curie Cancer Center-Institute of Oncology in Warsaw in the period 1979-1985, following primary surgery. The clinical stage of disease advancement was determined on the basis of surgery protocols and histological examinations. Radiotherapy was the treatment of choice in patients in stages I and II. Irradiation was applied to the pelvis minor and para aortal nodes (in patients at stage Ia) or to fields covering the entire abdominal cavity (other patients at stage I and II). Chemotherapy was given to stage III and IV patients multi-drug therapy, usually including Cisplatin, Adriamycin, and Cyclophosphamide, or with one drug (monochemotherapy) with the alhylating agents. The largest group of patients under study were women with ovarian cancer in stage I (38.8%), the smallest group consisted of patients in stage IV (8.5%). Patients in stage III represented 37.5% of all the material. Patients aged 50-64 years were most frequently treated (47.3%), the least frequent group were the patients aged over 65 (13.2%). The predominating histological diagnosis was serous cancer type (48.7%), clear-cell cancer was detected least frequently (13.2%). Among all the patients treated 35.4% survived 5 years after treatment, 69% in stage I, 43.8% in stage II, 8.8% in stage III, and 2.5% in stage IV.
Pietrzak
K
K
Department of Gynaecological Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology Warsaw, Poland.
Sablińska
B
B
Zieliński
J
J
D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D010052:Ovariectomy; D010166:Palliative Care; D011044:Poland / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D000477:Alkylating Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin